So what’s a potential leader? I could write about some of the (very few) stocks that are hitting new peaks–only 14 stocks hit new peaks on the NYSE and Nasdaq on December 18, for instance–but instead, I’m highlighting a company with huge growth, a big story, and whose stock is in the sixth week of building a good-looking base. It’s Myriad Genetics (MYGN), which I know has been mentioned in past Cabot Wealth Advisories. To review, the company is the leader in the new field of cancer predisposition testing. It has five tests on the market that tell patients...
